
Goldman Sachs has decided to maintain its Buy rating of Cytek Biosciences (NASDAQ:CTKB) and lower its price target from $14.00 to $12.00.
Shares of Cytek Biosciences are trading up 10.93% over the last 24 hours, at $8.22 per share.

Goldman Sachs has decided to maintain its Buy rating of Cytek Biosciences (NASDAQ:CTKB) and lower its price target from $14.00 to $12.00.
Shares of Cytek Biosciences are trading up 10.93% over the last 24 hours, at $8.22 per share.